Roughly 2.6 million people enrolled in a Medicare Advantage prescription drug plan in 2025 had their coverage terminated at the end of the year, as insurers discontinued plans or pulled out of specific areas. This reduction in availability follows a trend where government reimbursement rates fell by roughly 20% from 2023 levels by 2026, while medical costs continued to climb. Consequently, major carriers have shed unprofitable business to protect earnings, resulting in fewer choices for the average Medicare beneficiary.

Market Withdrawal and Service Area Reductions

The pullback among major carriers has been significant. UnitedHealth Group Inc. exited 225 counties for 2026 while entering only 14. Humana Inc. left 198 counties, reducing its service area to 85% of U.S. counties from 89%, and exited three states entirely. Additionally, the Aetna unit of CVS Health Corp. offered standalone Part D plans in approximately 100 fewer counties compared to the previous year.

Impact on Beneficiary Choices

The result of these strategic withdrawals is a contraction in market options. The average Medicare beneficiary had access to 32 Medicare Advantage prescription drug plans for 2026, a decrease from 34 plans available a year earlier. Research indicates that most individuals affected by plan terminations still have other Medicare Advantage options available, though replacement plans may not match the specific benefits or networks of the discontinued coverage.

Enrollment Windows and Protections

Beneficiaries affected by plan terminations have specific enrollment rights. Insurers are required to mail an Annual Notice of Change by the end of September, detailing modifications for the coming year, along with a separate non-renewal notice for discontinued plans. The Medicare Annual Enrollment Period runs from October 15 to December 7. However, those whose specific plans are terminated qualify for a Special Enrollment Period, allowing them to select a replacement plan without a coverage gap.

Strategic Implications for Insurers

For investors, the retreat from unprofitable markets represents a deliberate margin management strategy. Companies such as UnitedHealth, Humana, and CVS are prioritizing earnings stability over membership growth. The focus for investors has shifted toward how effectively insurers manage medical costs relative to government payments. Looking ahead to 2027, Medicare Advantage plans are projected to receive an average federal payment increase of about 2.48%, worth roughly $13 billion, which may moderate the pace of market exits.

UnitedHealth Group Inc. reported second quarter 2026 revenues of $112.032 billion and adjusted earnings per share of $6.38, surpassing analyst expectations. The company raised its full year 2026 adjusted earnings outlook to a range of $19.50 to $20.00 per share and projects GAAP EPS of $18.45-$18.95. Despite losing 965,000 Medicare Advantage members since the end of 2025, the strong performance drove shares higher in premarket trading.

For the quarter ended June 30, 2026, diluted earnings per share were $6.04. The medical cost ratio improved to 86.7% from 89.4% in the prior year, reflecting product design changes, pricing discipline, and improved medical cost management. The quarter also benefited from $860 million of favorable prior-period reserve development. Operating earnings climbed to $8 billion from $5.2 billion a year ago.

UnitedHealthcare served 48.5 million consumers, reporting revenues of $86.0 billion and earnings of $3.9 billion. Optum supported more than 120 million consumers, generating revenues of $65.7 billion and earnings of $4.0 billion, representing 160 basis points of margin expansion year-over-year. Optum highlighted continued investments in AI-enabled products, including autonomous coding and digital prior authorization tools.

Cash flows from operations were $11.1 billion, or 1.9 times net income. The debt-to-capital ratio was 41.2% as of June 30, 2026. The company repurchased $4.0 billion of its common stock through mid-July 2026 and is on track to repurchase at least $5.0 billion for the full year 2026.

Strategic Initiatives and AI Integration

Management emphasized a tech-forward approach, actively embracing an AI paradigm to modernize the health system. The company is using AI to improve service interactions, reduce administrative burden, and support better decision-making. Specific initiatives include a commitment to eliminate 30% of prior authorization volume and nearly two-thirds of prior authorization requirements for pediatric care by the end of the year. Optum Health is deploying AI-based ambient listening capabilities, available to 70% of employed providers and expected to exceed 90% by year-end, resulting in a 90% reduction in cognitive burnout for clinicians.

Leadership Philosophy: A Restless Approach

During the earnings call, CEO Stephen Hemsley introduced a recurring theme describing the company's mindset as "restless." Hemsley stated that UnitedHealth's progress was fueled by "a restless desire to drive mission-aligned change across the enterprise." When asked if the turnaround was complete, Hemsley indicated the company would "never will remain restless" and would always stay in "improvement and urgency mode." He emphasized that this is not just about returning to a growth rate but maintaining a broader mission that is a continuous journey. Executive Vice President Tim Noel echoed this sentiment regarding Medicare Star ratings, stating the company is "restless when it comes to seeking opportunities to differentiate."

Cost Trends and Medical Performance

Medical cost trends in Medicare are running below initial expectations of around 10% for 2026, driven by benefit design, care management models, and network curation. Conversely, commercial costs remain stubbornly high, rising modestly above the 11% level previously seen due to the independent resolution process under the No Surprises Act and aggressive provider billing practices. The company expects full-year Medicare Advantage enrollment to decline by approximately 1.1 million and Medicare margins to finish 2026 above 3%.

Second Quarter 2026 Key Performance Metrics

Outlook

UnitedHealth Group updated its full year 2026 guidance to reflect the strong performance. Adjusted net earnings are now expected to be between $19.50 and $20.00 per share, while GAAP EPS is projected to be $18.45-$18.95. The company projects cash flows from operations of approximately $24,000 million and share repurchases of at least $5,000 million. Management remains committed to a long-term growth target of 13-16%.

Analyst Reactions

Following the earnings announcement, several analysts revised their price targets. UBS analyst A.J. Rice maintained the stock with a Buy rating and raised the price target from $460 to $490. RBC Capital analyst Ben Hendrix maintained UnitedHealth with an Outperform rating and boosted the price target from $463 to $478. Truist Securities analyst David Macdonald maintained the stock with a Buy and raised the price target from $480 to $500.